Recursion Pharmaceuticals Inc (RXRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.83 (+8.19%), Market cap $1.56B, 52-week low–high $2.84 ~ $6.79.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4
Financial statements, price targets, institutional (13F) holdings and related news for Recursion Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Recursion Pharmaceuticals Inc trades at $3.83 (+8.19%). Real-time quotes and charts are available on BlackAll Trade.
Recursion Pharmaceuticals Inc has a market cap of about $1.56B.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, d